Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The 56 Point TA; Charts With an Attitude -- Ignore unavailable to you. Want to Upgrade?

To: Doug R who wrote (31990)	9/14/1999 9:15:00 AM
From: John Miz	Read Replies (1) \| Respond to of 79200

ALLP NEWS> biz.yahoo.com SAN DIEGO--(BW HealthWire)--Sept. 14, 1999--Alliance Pharmaceutical Corp. (Nasdaq:ALLP - news) announced today that it has reached agreement with the Food and Drug Administration (FDA) on the key design features of the Phase 3 program for Oxygent(TM), an intravascular oxygen carrier (''blood substitute'') intended to reduce the need for donor blood transfusions in surgical patients. Oxygent will be studied in a Phase 3 clinical (human) trial in the U.S. involving patients undergoing coronary artery bypass grafting (CABG) surgery under cardiopulmonary bypass (CPB). This study, which is expected to start shortly, will complement a Phase 3 trial currently underway with general surgery patients in eight European countries. Oxygent is the only blood substitute in clinical development that is formulated from a synthetic raw material (emulsified perflubron) and not derived from human or bovine blood.

To: Doug R who wrote (31990)	9/14/1999 1:39:00 PM
From: bdog	Read Replies (4) \| Respond to of 79200

Thanks for the rundown Doug. Woke up in time and dumped the dogs of the dog at the appropriate time and got CEGE and CBST. CBST looking strong at the moment... sorry Ken, but CEGE looked too inviting, hitting the M12 last night bdog

To: Doug R who wrote (31990)	9/14/1999 4:12:00 PM
From: Doug R	Read Replies (4) \| Respond to of 79200

The S&P and next month: 233,21,34 on S&P is crossing back up. It's still over 80. 89,3,5 very weak and crossing down. The 233 xover is likely to fail due to this. The 13 dRSI bounced off of line 3 last week and didn't hold line 2...now it's crossing back under line 3. A test of line 4 is imminent giving a couple weeks time if it bounces off line 4. The current progression through the series is typical of a correction building. A poor day tomorrow and I'll be out of the S&P for Oct. Doug R